Bausch Faces $3 Billion in Claims Left From Valeant Stock Suit

Bausch Health Cos.owes a group of investment funds more than $3 billion for stock losses caused by spurious accounting at its predecessor, Valeant Pharmaceuticals, investors suing the company alleged this week.

The payout model used by Bausch to settle related allegations in 2019 shows that at least 22 investors who rejected that deal should collect $3 billion, according to federal court papers filed July 27 in New Jersey. The investors want the judge overseeing the case to schedule a trial for next year on how much they should get.

The investors accused Bausch of trying to delay a trial, ...